Seattle, WA -- (SBWire) -- 10/17/2019 --Chronic lymphocytic leukemia (CLL) is one of the most common type of leukemia found in adults. It is a type of tumor, which is characterized by production of abnormal white blood cells in the bone marrow. Its symptoms are swelling of the lymph nodes, fatigue, fever, infection, pain beneath the ribs, and weight loss. Moreover, CLL is seldom observed in children and people aged 40 years and below, as it is more prevalent in geriatric population. Moreover, its causes unknown and is more severe than acute leukemia. In fact, its prevalence is more in males than females. Although, the incidence of this disorder is higher in white population than Asian populations, the precise cause for this cannot be explained.

CLL is diagnosed in various ways including Blood Cell Count and Examination, Bone Marrow Examination for patients followed by treatment. Its treatment includes single or combination drug therapy, monoclonal antibody therapies, targeted therapies, and white blood cell (neutrophil) growth factors. Moreover, radiation therapy and splenectomy are also used for the treatment albeit in rare cases.

Request Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/2049

Global Chronic Lymphocytic Leukemia Therapeutics Market - Drivers

Growing prevalence of CLL coupled with its high mortality rate is expected to drive growth of the global chronic lymphocytic leukemia therapeutics market during the forecast period. According to the American Cancer Society (ACS), in 2017, around 20,110 new cases of chronic lymphocytic leukemia and 4,660 deaths from CLL were expected to occur in the U.S. Furthermore, high prevalence of CLL in geriatric population is also expected to increase demand for chronic lymphocytic leukemia therapeutics and thereby support the market growth. According to the United Nations data, in 2015, around 901 million people in the world were aged 60 years and above. According to the same source this number is expected to reach 1.4 billion by 2030 and to 2.1 billion by 2050.

Constant research and development activities are expected contribute to the development of new treatments related to tumors, including impaired immune system, genetic factors, and viruses, which in turn, is expected to boost the market growth during the forecast period.

Furthermore, growing occurrences of comorbidities, especially among geriatric population and increasing launch of new pipeline drugs are major factors driving growth of the global chronic lymphocytic leukemia therapeutics market. For instance, in December 2015, Bendeka injection, manufactured under the collaboration of Teva Pharmaceuticals Industries Ltd. and Eagle Pharmaceuticals Inc., received the U.S. Food and Drug Administration (FDA) approval for the treatment of patients with CLL and indolent B-cell non-Hodgkin lymphoma (NHL) — progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

However, high costs and side effects related these drugs is expected to hinder growth of the market over the forecast period.

Global Chronic Lymphocytic Leukemia Therapeutics Market – Regional Analysis

Among regions, North America accounted for the largest market share in 2016, owing to high presence of breakthrough pipeline drugs. For instance, the drug Acalabrutinib—manufactured by Acerta Pharma BV—is under phase 2 clinical trial for the treatment of CLL and small lymphocytic lymphoma (SLL). The study is estimated to complete in January 2019.

Moreover, North America is expected to witness significant growth in chronic lymphocytic leukemia therapeutics market during the forecast period. This is owing to increasing research and development activities couple with increasing prevalence of CLL in the U.S. According to the Leukemia & Lymphoma Society, US, in 2013, there were around 119,386 patients in the U.S., which increased to 15,720 in 2014.

Global Chronic Lymphocytic Leukemia Therapeutics Market – Competitor Analysis

Keyu players operating in the global chronic lymphocytic leukemia therapeutics market include, F. Hoffmann-La Roche Ltd, Novartis International AG, GlaxoSmithKline Pharmaceuticals Limited, Celgene Corporation, Genmab A/S, Abbvie Inc. Teva Pharmaceutical Industries Ltd., Biogen Idec, AstraZeneca plc, Arno Therapeutics, Genzyme Corporation, Gilead Sciences Inc., and others.

Some Important TOC:

- Market Overview
- Global Chronic Lymphocytic Leukemia Therapeutics Market Landscape by Player
- Players Profiles
- Global Production, Revenue (Value), Price Trend by Type
- Market Analysis by Application
- Global Chronic Lymphocytic Leukemia Therapeutics Production, Consumption, Export, Import by Region (2013-2018)
- Production, Revenue (Value) by Region (2013-2018)
- Chronic Lymphocytic Leukemia Therapeutics Manufacturing Analysis
- Industrial Chain, Sourcing Strategy and Downstream Buyers
- Market Dynamics
- Global Chronic Lymphocytic Leukemia Therapeutics Market Forecast (2018-2026)
- Research Findings and Conclusion
- Appendix

To Conversation With Our Analysts Click @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2049

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.